259 related articles for article (PubMed ID: 30172479)
21. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience.
Chen KS; Berhane H; Gill BS; Olawaiye A; Sukumvanich P; Kelley JL; Boisen MM; Courtney-Brooks M; Comerci JT; Edwards R; Berger J; Beriwal S
Gynecol Oncol; 2017 Nov; 147(2):315-319. PubMed ID: 28866431
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
[TBL] [Abstract][Full Text] [Related]
24. Impact of adjuvant treatment on outcome in high-risk early-stage endometrial cancer: a retrospective three-center study.
Helpman L; Perri T; Lavee N; Hag-Yahia N; Chariski HA; Kalfon S; Derazne E; Beiner ME; Kadan Y; Fishman A; Korach J; Covens A; Gien L
Int J Gynecol Cancer; 2019 Jan; 29(1):133-139. PubMed ID: 30640695
[TBL] [Abstract][Full Text] [Related]
25. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
26. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
27. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
Forsse D; Berg HF; Bozickovic O; Engerud H; Halle MK; Hoivik EA; Woie K; Werner HMJ; Haldorsen IS; Trovik J; Krakstad C
Gynecol Oncol; 2021 Feb; 160(2):396-404. PubMed ID: 33317908
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemoradiotherapy vs. radiotherapy alone in early-stage high-risk endometrial cancer: a systematic review and meta-analysis.
Jingjing H; Rui J; Hui P
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):833-840. PubMed ID: 30720192
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
[TBL] [Abstract][Full Text] [Related]
30. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
[TBL] [Abstract][Full Text] [Related]
31. Radiation, chemotherapy or combined modality therapy in adjuvant treatment for stage III endometrial carcinoma in lower southern Thailand: disease recurrence and overall survival.
Pichatechaiyoot A; Buhachat R; Boonyapipat S; Kanjanapradit K
J Med Assoc Thai; 2014 Mar; 97(3):274-82. PubMed ID: 25123006
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
34. Mismatch repair status in high-grade endometrial carcinomas of endometrioid and non-endometrioid type.
Doulgeraki T; Vagios S; Kavoura E; Yiannou P; Messini I; Nonni A; Papadimitriou C; Vlachos A; Pavlakis K
J BUON; 2019; 24(5):2020-2027. PubMed ID: 31786870
[TBL] [Abstract][Full Text] [Related]
35. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
36. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
37. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
[TBL] [Abstract][Full Text] [Related]
38. Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy.
Russo AL; Lee LJ; Wo JY; Niemierko A; Park D; Alban G; King M; Philp L; Growdon WB; Oliva E; Spriggs DR; Yeku OO
Am J Clin Oncol; 2022 Jan; 45(1):36-39. PubMed ID: 34817442
[TBL] [Abstract][Full Text] [Related]
39. Role of adjuvant radiotherapy in FIGO stage IIIC endometrial carcinoma: Treatment outcomes and prognostic factors in 52 irradiated patients.
Hsieh HY; Wang L; Lu CH; Lin JC; Chen CC
J Formos Med Assoc; 2018 Jul; 117(7):613-620. PubMed ID: 28867455
[TBL] [Abstract][Full Text] [Related]
40. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
